Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CTSO

Cytosorbents Q3 2026 Earnings Date & Estimates

Cytosorbents logo
$3.06 -0.03 (-0.97%)
Closing price 03:50 PM Eastern
Extended Trading
$3.15 +0.09 (+2.91%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytosorbents is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cytosorbents in Q3 2026

Cytosorbents is expected to post earnings of -$0.90 per share on revenue of $9.90 million. In the same quarter a year earlier Cytosorbents reported -$0.80 per share on revenue of $9.49 million. Cytosorbents last reported on August 6, 2026, posting -$0.07 per share and beating the -$0.80 consensus estimate. Cytosorbents has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.90
Expected Revenue
$9.90 million
Prior-Year EPS
-$0.80
Prior-Year Revenue
$9.49 million
Expected Revenue Growth
+4.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Beat by +$0.73)
Last Quarter Revenue
$9.63 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Cytosorbents Q3 2026 Earnings FAQ

Cytosorbents (NASDAQ:CTSO) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Cytosorbents' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cytosorbents to post earnings of -$0.90 per share for Q3 2026.

The consensus revenue estimate for Cytosorbents is $9.90 million for Q3 2026.

Cytosorbents Earnings Headlines

Analyzing Cytosorbents (NASDAQ:CTSO) and Electromed (NYSE:ELMD)
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107926
Contrasting Trinity Biotech (NASDAQ:TRIB) & Cytosorbents (NASDAQ:CTSO)
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107784
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
October 15 at 1:00 AM  |  Profits Run (Ad)
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-cardiac-surgery-and-critical-care-302894072.html
Cytosorbents Corp
September 25, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/ctso-cytosorbents-corp/vitals
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/cytosorbents-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302887243.html
See More Cytosorbents Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email.

About Cytosorbents

Cytosorbents (NASDAQ:CTSO) is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness.

The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems. CytoSorbents has also developed additional products and investigational therapies for applications including cardiac surgery, kidney disease, liver failure and other conditions in which blood purification may be beneficial.

Founded in 2001 and headquartered in Princeton, New Jersey, CytoSorbents serves healthcare markets internationally through direct sales and distribution partners. Its products have received regulatory clearances or approvals in various jurisdictions, including Europe, while other products and applications remain under clinical or regulatory review in certain markets.

View Cytosorbents Profile
Earnings Tools